中文Laos Vientiane-October 10, 2023-BigBear Pharma, a leading alchemon company focusing on development and commercial cancer innovation therapy,
announced today that two products have been approved by the Ministry of Health of Laos.
The approved drugs are:
Pomalidomide: Sell with the PommadX brand name. Potamine is an immune regulatory drug that belongs to the "caffeine control" targeted drug. It affects
the production of the immune system and regulating the inflammatory factors to achieve the effect of treating malignant tumors. Potamidamine is often
used in Multiple MyEeloma, which has been treated for treatment but still has the progress of the disease.
PEMIGATINIB: Sell with the PemidX brand name. Pemitinib is a targeted therapy, a tyrosine kinase inhibitor. It suppresss into a fibroblast growth factor receptor.
It is used to treat irrevised, local advanced or metastatic bile duct cancer with fibroblast growth factor receptor (FGFR2) gene changes. It is used to recur or
refractory medulla/lymph -like tumor (MLN) with fibroblast growth factor receptor 1 (FGFR1). Pemininib has accelerated the treatment of patients with
fibroblast growth factor receptor 2 (FGFR2) in 2020 for the treatment of patients with fibroblasts (FGFR2) in 2020.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.